MINOCIN^®—the only pelletized-release form of minocycline

• Virtually complete (>95%) absorption¹
  — The effect of food and dairy is not significant¹
• Sustained therapeutic levels with a long half-life (mean 15.5 hours-fed state)²
  — Serum levels exceed MIC₉₀s for P acnes (0.25?g/ml) at 24 hours-fed state/single dose^2,3
  — Excellent tissue levels at 1 and 3 weeks²
  
• Minimal resistance
  — In an in vitro study of antibiotic-resistant P acnes, the majority of tetracycline-resistant strains were cross-resistant to doxycycline but sensitive to minocycline†⁴

†In vitro activity does not necessarily correlate with in vivo activity.
References: 1. Saivin S, Houin G: Clinical pharmacokinetics of doxycycline and minocycline. Clinical Pharmacokinet. 1988;15:355-366. 2. MacDonald H, Kelly RG, Allen ES, et al. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther. 14:852-861. 3. Denys GA, Jerris RC, Swenson JM, et al. Susceptibility of Propionibacterium acnes clinical insolates to 22 antimicrobial agents. Antimicrob Agents Chemother. 1982;23:335-337. 4. Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline, Br J Dermatol. 1993;128:556-560.

›››  MINOCIN-delivers the power to clear lesions rapidly